HL7 FHIR Implementation Guide: Breast Cancer Data, Release 1 - US Realm (Draft for Comment 2)

Primary value sets defined as part of this Implementation Guide

Name Definition
AnatomicalDirectionVS

Anatomical location or specimen further detailing directionality. Codes are from NCI

AnatomicalLocationVS

Codes that describe normal and pathologic anatomic systems, regions, cavities, and spaces.

BreastCancerDetectionVS

The method with which breast cancer was detected.

BreastCarcinomaHistologicTypeVS

Histologic types of breast carcinomas, including invasive carcinoma and ductal carcinoma in situ. Codes are drawn from SNOMED CT; local codes are used where SNOMED CT codes are unavailable. The codes are intended to match the scope of breast carcinoma histologic types specified in ICD-O-3. Additional SNOMED CT codes may be appropriate to include in this value set. We are requesting feedback on the perceived need to request SNOMED CT codes to represent the histologic types currently represented by local codes.

BreastLymphNodeGroupVS

The regional lymph node locations

BreastSiteVS

Topography of the breast. Codes are drawn from SNOMED CT and can be regarded as equivalent to ICD-O-3 topography codes.

BreastSpecimenCollectionMethodVS

The surgical method used to obtain the tissue sample.

BreastSpecimenTypeVS

The type of specimen obtained from the breast. Codes are drawn from SNOMED CT where available. Local codes are used where Snomed codes are currently unavailable.

ClockDirectionVS

The relative direction of an object described using the analogy of a 12-hour clock to describe angles and directions. One imagines a clock face lying either upright or flat in front of oneself, and identifies the twelve hour markings with the directions in which they point.

DCISNuclearGradeVS

The nuclear grade describes how closely the nuclei of cancer cells look like the nuclei of normal breast cells. In general, the higher the nuclear grade, the more abnormal the nuclei are and the more aggressive the tumor cells tend to be. In breast cancer, nuclear grade is typically evaluated for ductal carcinoma in situ (DCIS) only.

EstrogenReceptorInterpretationTestsVS

Laboratory observations holding the interpretation of estrogen receptor status (e.g. positive, negative).

HER2FISHMethodVS

Value set containing In Situ Hybridization methods of determining HER2 status

HER2byFISHVSInterpretationTestsVS

Laboratory observations holding the interpretation of FISH HER2 receptor tests (e.g. positive, negative, equivocal)

HER2byIHCInterpretationTestsVS

Laboratory observations holding the interpretation of immunohistochemistry HER2 receptor tests (e.g. positive, negative, equivocal).

HER2byIHCScoreVS

Value set containing possible scores resulting from determining HER2 status by immunohistochemistry. Based on LNC#LL4396-9 answer list.

Ki-67NuclearAntigenVS

An evaluation of the quantitative value from the Ki-67.

LymphNodeClinicalMethodVS

The method of lymph node sample collection for clinical LNI assessment.

LymphNodeInvolvementVS

The pathological finding for lymph node involvement.

LymphNodeMobilityVS

Values expressing the degree of moveability of lymph node upon palpation.

LymphNodeSamplingMethodVS

The procedure method used to obtain the specimen analyzed for the pathological lymph node involvement.

MorphologyBehaviorVS

The morphologic behavior of the cancer. These are equivalent to the suffix to the ICD-O-3 histologic type codes.

PositiveNegativeEquivocalIndeterminateVS

Interpretation of a test result as positive, negative, equivocal, or indeterminate.

PositiveNegativeIndeterminateVS

Value set containing the values positive, negative and indeterminate. Equivalent to values in LOINC answer list LL2038-9/LL759-2

PositiveNegativeVS

Value set containing the values positive and negative. VSAC value set OID 2.16.840.1.113762.1.4.1166.62.

ProgesteroneReceptorInterpretationTestsVS

Laboratory observations holding the interpretation of progesterone receptor status (e.g. positive, negative).

RecurrenceRiskScoreInterpretationVS

Interpretations of risk as high, intermediate, or low. Answer set taken from LOINC LL3198-0.

StageTimingPrefixVS

When staging was done, relative to treatment events (qualifier).

StainingIntensityVS

Staining intensity, to be reported as weak, moderate, or strong.

TumorMarginDescriptionVS

An evaluation of the lesion around the margins surrounding the tumor.